A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study) [0.03%]
生物週期劑量escalation替氟酰胺/チピラセタ联合贝伐珠单抗治疗结直肠癌二期研究(E-BiTS研究)
M Wakabayashi,H Taniguchi,A Makiyama et al.
M Wakabayashi et al.
Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) remains a standard of care for refractory metastatic colorectal cancer (mCRC), though hematological toxicities remain a concern. Although a biweekly regi...
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy [0.03%]
新辅助化疗后三阴性乳腺癌患者术后卡培他滨辅助治疗的效果
A Strahan,Q Jin,A S Raghavendra et al.
A Strahan et al.
Background: For patients diagnosed with triple-negative breast cancer (TNBC), residual disease (RD) after neoadjuvant chemotherapy (NAC) is associated with increased rates of recurrence and poor prognosis. Adjuvant therap...
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC [0.03%]
肾细胞癌患者使用免疫检查点抑制剂治疗基线和过程中自身抗体谱分析-TITAN-RCC研究的探索性结果
A Fritzsch,K Leucht,N Röber et al.
A Fritzsch et al.
Background: Immune checkpoint inhibitor (ICI) administration profoundly promotes T-cell-mediated antitumor effects, but also frequently causes the development of immune-related adverse events (irAEs) in cancer patients. P...
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation [0.03%]
基于传统和人工智能的临床预测模型在非小细胞肺癌中的应用:从开发到真实世界验证
H R Howard,M Hasanova,A Tiwari et al.
H R Howard et al.
Globally, lung cancer remains the most common cause of cancer mortality, with non-small-cell lung cancer (NSCLC) being the most common subtype of lung cancer diagnosed. This review paper provides a comprehensive landscape of clinical predic...
Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial [0.03%]
高危复发局部晚期结肠癌新辅助FOLFOXIRI化疗单臂II期临床试验
Y-W Zhou,G-X Wei,X-R Chen et al.
Y-W Zhou et al.
Background: To evaluate the safety and deliverability of neoadjuvant chemotherapy (NAC) with three-drug-intensity chemotherapy [oxaliplatin, irinotecan, and fluorouracil (FOLFOXIRI)] in patients with high-risk factors for...
Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers [0.03%]
英国李-弗拉莫尼综合征的临床特征及TP53基因携带者的预后情况
E Finn,S Sardo Infirri,C S Clarke et al.
E Finn et al.
Background: Li Fraumeni syndrome (LFS), a rare genetic condition, poses a significant health impact due to the ∼75%-90% lifetime risk of developing cancer in affected individuals. Due to the rarity of this disease, littl...
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study [0.03%]
III期不可切除非小细胞肺癌患者放疗后的德瓦鲁单抗治疗:DUART二期非随机对照研究
A R Filippi,M R García Campelo,J-B Paoli et al.
A R Filippi et al.
Background: Currently, patients with unresectable stage III non-small-cell lung cancer (NSCLC) ineligible for chemotherapy receive radiotherapy alone, with unsatisfactory results. DUART was a phase II single-arm trial of ...
Trastuzumab deruxtecan adverse drug reactions reported to the UK's Medicines and Healthcare products Regulatory Agency via the Yellow Card Reporting System [0.03%]
英国通过黄卡系统报告的注射曲妥珠单抗deruxtecan不良反应事件
J Pearson,M Pirmohamed,C Palmieri
J Pearson
Improving chemotherapy-induced peripheral neuropathy in cancer patients using a combined qigong and self-administered acupressure intervention: a randomized controlled trial [0.03%]
改善癌症患者化疗诱发的周围神经病变的气功和自我穴位按压联合干预的随机对照试验
D S T Cheung,W F Yeung,P H Chau et al.
D S T Cheung et al.
Background: Acupressure and qigong are Chinese medicine-based modalities that can work in synergy to improve chemotherapy-induced peripheral neuropathy (CIPN). This study examines the effect of a combined qigong and acupr...